BMO Capital lowered the firm’s price target on Medpace (MEDP) to $400 from $460 and keeps a Market Perform rating on the shares. The company’s results were well ahead of consensus, but another quarter of elevated cancellations combined with weaker gross wins weigh heavily on both the longer-term growth outlook and investor sentiment, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: